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Abstract
Immunosuppression by retroviruses including the human immunodeficiency virus—1 (HIV-
1) is well known, however the mechanisms how retroviruses induce this immunosuppres-
sion is not fully investigated. It was shown that non-infectious retroviral particles as well as
retroviral or recombinant retroviral transmembrane envelope (TM) proteins demonstrated
immunosuppressive properties. The same was shown for peptides corresponding to a
highly conserved domain in the TM protein. This domain is called immunosuppressive (ISU)
domain and it induces modulation of the cytokine release of peripheral blood mononuclear
cells (PBMCs) from healthy donors. In addition, it changes the gene expression of these
cells. Common indications for the immunosuppressive activity were tumour growth in vivo
and interleukin—10 (IL-10) release from human PBMCs in vitro. Single mutations in the ISU
domain abrogated the immunosuppressive activity. In order to develop a new model system
for the expression of the ISU domain and presentation to PBMCs which is not prone to pos-
sible endotoxin contaminations, two expression systems were developed. In the first sys-
tem, designated pOUT, retroviral proteins containing the ISU domain were expressed and
released into the cell culture medium, and in the second system, tANCHOR, the ISU domain
was presented by a tetraspanin-anchored sequence on the cell surface of human cells. Both
systems were exploited to express the wild-type (wt) ISU domains of HIV-1, of the porcine
endogenous retrovirus (PERV) and of the murine leukaemia virus (MuLV) as well as to
express mutants (mut) of these ISU domains. PERV is of special interest in the context of
virus safety of xenotransplantation using pig organs. Expression of the TM proteins was
demonstrated by confocal laser scanning microscopy, ELISA and Western blot analyses
using specific antibodies. However, when cells expressing and releasing the ISU were co-
incubated with human PBMCs, no increased production of IL-10 was observed when com-
pared with the mutants. Similar results were obtained when the released TM proteins were
concentrated by immunoprecipitation and added to PBMCs. We suggest that the absence
of IL-10 induction can be explained by a low amount of protein, by the lack of a biologically
active conformation or the absence of additional factors.
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Introduction
Retroviruses are like many other viruses including the measles virus (MV) and the human
cytomegalovirus (HCMV) immunosuppressive. The mechanisms how viruses induce immu-
nosuppression in the infected host are different and not fully elucidated. In the case of the MV,
viral proteins effectively inhibit the induction of the innate immunity, especially the interferon
production [1]. The persistence of the virus for many months indicates a prolonged immuno-
suppression and secondary infections occur because of it [2]. Measles-related symptoms are
associated with lymphopenia and depletion of lymphocytes from lymphoid tissues [3]. MV
proteins actively silence T cells by interfering with signalling pathways essential for T-cell acti-
vation and the MV glycoprotein complex was shown to activate cellular sphingomyelinases
and to interfere with Akt kinase activation [4]. Suppressed immune responses in measles virus
infections are also associated with an increased IL-10 production by neutrophils and mono-
cytes may [5–7].
To coexist with its host, HCMV uses different mechanisms to enable the virus to remain
invisible to cells of the immune system and to induce a general suppression of the immune sys-
tem [8]. Viral proteins inhibit NK cell, helper T and cytotoxic T cell responses and target the
humoral immune response. The virus also controls the production of cytokines and chemo-
kines and stimulates local inflammation [9]. In addition, HCMV-encoded homologs of G pro-
tein-coupled receptors and chemokines play an important role in evasion from the immune
system [10]. Furthermore, microRNAs regulate viral and cellular transcripts to favour viral
infection and to inhibit the host‘s antiviral immune response [11, 12].
There is accumulating evidence that in the case of retroviruses also a viral protein, the trans-
membrane envelope (TM) protein, play a role in virus-induced immunosuppression [13, 14].
The human immunodeficiency virus type 1 (HIV-1) and HIV-2 as well as other retroviruses,
e.g., gammaretroviruses such as the murine leukaemia virus (MuLV), the feline leukaemia
virus (FeLV) and the koala retrovirus (KoRV) induce immunosuppression in the infected host
(for review see [13, 14]). Non-infectious virus particles, purified viral or recombinant TM pro-
teins were found immunosuppressive in different in vitro and in vivo assays. In mice, certain
tumour cells grow to tumours in animals which are immunocompromised, but not in immu-
nocompetent mice. Expression of TM proteins from different retroviruses on these cells
allowed them to grow to tumours even in immunocompetent animals [15, 16]. This indicates
that the TM proteins suppress the immune system und prevent tumour rejection. To localise
the biologically active domain in the TM proteins, synthetic peptides were used and a domain
in the C-terminal part of the N-helical repeat, the so-called immunosuppressive (ISU) domain
was identified [17, 18] (Fig 1A). The ISU domain is highly conserved among retroviruses [14].
Synthetic 17- to 19-mer peptides corresponding to the ISU domain of gammaretroviruses or
HIV-1 inhibited proliferation of PBMCs and modulated their cytokine release. For example,
they caused an increase of IL-10 and had an inhibitory effect on protein kinase C (PKC) [14,
18–26]. Recombinant gp41 produced in bacteria [27–29] or human cells [30, 31] also modu-
lated cytokine expression of PBMCs from healthy donors. Single mutations in the ISU domain
abrogated the ability of retroviral ISU domains to cause IL-10 release and to modulate gene
expression [30]. Single mutations also abrogated tumour growth in vivo in the murine experi-
mental system described above [16, 32] and improved the efficacy of an antiretroviral vaccine
[33]. Replication competent HIV-1 particles with such mutations in the ISU domain of gp41
did not induce IL-10 release, whereas the wild-type virus did [30].
Working with recombinant retroviral proteins produced in bacteria bears the risk that they
are contaminated with endotoxin. Endotoxin induces similar, but not identical changes in the
cytokine release by human PBMCs [31]. In addition, production of TM proteins in human
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cells and their release is not very effective and requires concentration of large amounts of cul-
ture fluid with the risk of endotoxin contamination. Therefore, here two new endotoxin-free
expression systems for “one-pot protein expression and biological evaluation of IL-10 induc-
tion” were developed. In addition to the ISU domain of HIV-1, the ISU domain of PERV and
MuLV were analysed. PERVs are of interest because these porcine viruses may be transmitted
Fig 1. The pOUT expression system and analysis of the expressed proteins. (A) Schematic presentation of the vector and sequences of the corresponding ISU
domains. Retroviral TM protein sequences containing the ISU domain are fused N-terminally to a secretion sequence (signal peptide) from the luciferase gene of
Gaussia princeps, V5 and 6xHis tags are located in the C-terminus. The ISU domain protein sequences of HIV-1, PERV and MuLV and their mutated versions are
shown. (B) Western blot analysis of the secreted His-tagged TM protein of HIV-1 and PERV containing the ISU domain. The proteins were concentrated by an His Tag
Dynabeads pulldown, an anti-V5 antibody was used. (C) Western blot analysis of the His-tagged TM protein fragments in the supernatant and in the cell lysate of
transfected cells using antibodies against the V5 tag. Proteins of PERV and MuLV with and without mutations in the ISU domain were analysed.
https://doi.org/10.1371/journal.pone.0200570.g001
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during xenotransplantation using pig cells, tissues or organs to the human recipient and may
cause zoonotic infections [34]. MuLVs were the first retroviruses to prove that immunosppres-
sion occurs in its natural host species (for review see [13, 14]). The protein sequence of the ISU
domain of PERV is identical to the sequences of ISU domains of FeLV, MuLV, and KoRV
[14].
Retroviral TM proteins of HIV-1, PERV and MuLV are type I membrane proteins. They
are anchored with a C-terminal membrane spanning domain (MSD) in the virus membrane.
The TM protein gp41of HIV-1 is highly modified by N-linked glycans, but the p15E proteins
of PERV, KoRV and MuLV are not glycosylated [35–37]. In order to study the immunosup-
pressive properties of the TM proteins, sequences of the TM proteins containing the ISU
domain were selected. Two approaches were used. First, a cell system was established which
highly efficiently secretes native retroviral TM proteins which were used to analyse their
immunosuppressive properties. To obtain a high secretion rate, an efficient N-terminal signal
peptide derived from the luciferase of the Gaussia princeps organism was used. This signal pep-
tide was shown to allow a very effective secretion [38, 39]. Fusion of this signal peptide to ret-
roviral proteins facilitated secretion of these proteins into the culture medium of human
producer cells. The second approach was based on the surface expression of a part of the TM
protein containing the ISU domain using the tetraspanin CD82.
Results
Expression of the ISU domains in the pOUT system
Using the newly developed pOUT system, the TM proteins of HIV-1, PERV and MuLV and
their mutants were expressed in HeLa or HEK293T cells and secreted into the supernatant.
The extracellular parts of the TM proteins containing the ISU domain and C-terminal V5 and
6xHis tag sequences were expressed under the control of the CMV promoter (see Materials
and methods) (Fig 1A and S1 Fig). For a high secretion performance a signal peptide derived
from the Gaussia luciferase gene (Gaussia princeps) was used [38]. Efficient secretion was
shown for the wt ISU domains of HIV-1, PERV and MuLV and the corresponding mutants
(mut) by Western blot analysis using antibodies against the V5 tag (Fig 1B and 1C). The
expression of the ISU domain of PERV was—in contrast to that of MuLV—observed mainly
intracellular (Fig 1C). Comparing the sequences of the TM proteins of both viruses the only
difference was an arginine repeat in the protein sequence of p15E of PERV (Fig 2). The short
arginine repeat suggests that this protein was retained in the cells, because arginine/serine rich
proteins are mainly localised in the cytoplasm and are targeted to the nucleus [40, 41].
In order to quantify the amount of ISU proteins in the supernatant of pOUT protein-releas-
ing cells, an ELISA was performed using NTA-Ni(2+) chelate-coated plates. The collected and
concentrated supernatants from cells secreting proteins containing sequences of wt HIV, mut
HIV, wt PERV and mut PERV were added to the wells of the plates, detected by an HRP conju-
gated anti-His antibody and the absorbance was measured at 450 nm. Using a standard titra-
tion curve of the HIS-tagged glycoprotein B (gB) from the human herpesvirus 6 (HHV-6),
which was produced in our laboratory in highly purified quality [42] (S2 Fig), the protein
amount was estimated, between 262 and 410 ng/ml were found secreted (Fig 3A). When the
concentrated protein samples were analysed using the LAL assay, a contamination with a low
amount of LPS (ranging from 0.2–0.3 EU/ml) was observed (Fig 3B).
Expression of the ISU domains in the tANCHOR system
In the tANCHOR expression system, the ISU domain was included into the sequence of the
tetraspanin CD82, substituting the second extracellular loop (EC2, large external loop, LEL).
Retroviral immunosuppressive domains
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The construct contained a FLAG tag and a mCherry sequence as a reporter protein (Fig 4A
and 4B). The CD82-anchored and mCherry-tagged retroviral TM proteins were expressed in
HeLa cells and confocal laser scanning microscopy analysis revealed that the expressed pro-
teins are localised mainly in the plasma membrane. The co-localisation with the wild-type pro-
tein CD82 fused to YFP demonstrated that they are predominantly expressed on the cell
surface with an extracellular orientation (Fig 4C). The rate of expression of the wild-type and
mutated retroviral proteins was identical as demonstrated by Western blot analysis (Fig 4D).
Further, the transfection efficiency of every performed transfection was comparable (S3 Fig).
Expression of the wt and the mut proteins were approximately identical when the expression
in HeLa cells was analysed by Western blot (Fig 4E).
In order to investigate the extracellular accessibility of the expressed ISU domain, binding
of the monoclonal antibody B3, which is specific for the ISU domain of HIV-1, was analysed
Fig 2. Sequence alignment of the TM proteins p15E of PERV (GenBank AY312520.1) and MuLV (GenBank GQ420673.1). The arginine rich sequence in the p15E
of PERV is framed in red.
https://doi.org/10.1371/journal.pone.0200570.g002
Fig 3. Characterisation of the concentrated TM proteins of HIV-1, PERV, and MuLV. (A) Quantification of the TM proteins using an ELISA-based method. Ni(2+)
chelate-coated 96 well plates are used to quantify 50 μl of batches which are 40 x concentrates of secreted TM proteins. To quantify the concentration of collected and
secreted TM proteins a standard curve of highly purified polyhistidine tagged gB protein from HHV-6 was used (S2 Fig) (B) Results of LAL testing using 50 μl
concentrated supernatants, samples were measured in duplicates.
https://doi.org/10.1371/journal.pone.0200570.g003
Retroviral immunosuppressive domains
PLOS ONE | https://doi.org/10.1371/journal.pone.0200570 July 12, 2018 5 / 18
by a cell-based ELISA technique. The monoclonal antibody has been obtained by immunisa-
tion of a mouse with the synthetic ISU peptide conjugated to bovine serum albumin (BSA)
and selection by an ELISA using immobilised ISU peptide, the epitope ILAVERYL was deter-
mined using overlapping peptides (Andreas Hoffmann, Joachim Denner, Paul Ehrlich Insti-
tute, Langen, unpublished data). Purified IgG were used in this cell-based ELISA. Binding of
the ISU-specific IgG to the synthetic ISU peptide, and to cells expressing the wt ISU domain of
HIV-1, but not to control cells was observed (Fig 4G).
Influence of the immunosuppressive domains on cytokine release
To analyse whether the ISU domains are able to induce expression of IL-10 in vitro, in human
PBMCs, first, cells expressing the tANCHOR and the pOUT constructs were co-incubated
with human PBMCs. Second, concentrated supernatants of cells expressing the pOUT
Fig 4. The tANCHOR expression elements and protein expression analysis. (A) Schematic presentation of the main expression elements. Retroviral TM sequences
containing the ISU domain are fused N-terminally to a FLAG tag and the CD82 TM1-3 sequences and C-terminally to the CD82TM4 and mCherry sequences. The
protein sequences of the HIV-1 and PERV TM part containing the ISU domain (framed or marked grey) and the corresponding mutants (mutations are underlined) are
shown. (B) Schematic presentation of the tANCHOR membrane spanning proteins. The constructs contain the ISU domain instead of the LEL of CD82 (CD82ΔLEL).
The FLAG tag is shown in yellow, the mCherry protein in red. (C) Confocal laser scanning microscopy images of HeLa cells expressing the CD82 anchored retroviral
protein sequences tagged C-terminally with mCherry. In parallel a vector expressing the full-length protein sequence of CD82 under a CMV promoter and fused to YFP
was used as a control. The merged image shows a similar cellular localisation. (D) Comparison of the protein expression in human cell-lines. Western blot analysis of the
expressed CD82 anchored retroviral protein sequences in HeLa and HEK293T cells using anti-mCherry antibodies. Antibodies against beta actin were used as loading
control. (E) Analysis of the protein expression level on cells used in these experiments. HeLa cells are transfected with the vectors (1) pCMV-CD82ΔLEL-HIV-WT, (2)
pCMV-CD82ΔLEL-HIV-MUT, (3) pCMV-CD82ΔLEL-PERV-WT and (4) pCMV-CD82ΔLEL-PERV-MUT, cell lysates are analysed by Western blot analysis using
anti-mCherry antibody. Detection of CD9 using specific antibodies was used as loading control. (F) Protein expression analysis by detection of the mCherry
fluorescence in 96 well plates. (G) Detection of the ISU domain expressed on the surface of cells expressing the HIV-1 tANCHOR construct. A cell-based and a peptide-
based ELISA were performed using a purified IgG preparation of a monoclonal antibody specific for the ISU domain, synthetic ISU peptide was used as positive control,
non-transfected cells were used as negative control.
https://doi.org/10.1371/journal.pone.0200570.g004
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constructs were added to human PBMCs, and in both cases the release of IL-10 was measured.
When cells, which were transfected with different concentrations of pOUT constructs encod-
ing for the ISU domains of HIV-1 or PERV were co-incubated with human PBMCs, low
amounts of IL-10 were released and no significant differences between the wildtype and
mutated proteins were observed. Although the amount of released IL-10 was higher compared
with the amount released after incubation of human PBMCs with the supernatant from non-
transfected HeLa cells (p = 5.93E-12) (Fig 5A), the constructs expressing the wild-type and the
mutated versions of the ISU domain of HIV-1 and PERV gave the same results. The same was
observed when cells expressing the tANCHOR constructs were incubated with human PBMCs
(p = 5.81E-12) (Fig 5B). Altogether experiments with six different donors were performed (Fig
5A and 5B). In all cases lipopolysaccharide (LPS) served as a positive control inducing concen-
tration-dependent high amounts of IL-10 (Fig 5A and 5B). No IL-10 was released when the wt
and the mutant of the ISU domain of MuLV were expressed in HeLa cells and these cells were
co-incubated with human PBMCs (Fig 5A, Donor 04/08). Notably, heat inactivation of the
concentrated supernatants allowed to differentiate between protein based and heat-resistant,
possible LPS-based IL-10 induction. The decrease of IL-10 release after heat treatment indi-
cates the presence of a protein able to induce IL-10, however no differences in IL-10 produc-
tion levels between wt and mut protein samples were observed (Fig 5C).
As we had been shown previously, PBMCs from different donors reacted differently to
identical batches of ISU peptide homopolymers [26]. To make sure that the negative result,
e.g., absence of increased IL-10 release after incubation of human PBMCs with ISU-expressing
cells, is not due to a low-responder donor, the experiment was repeated with PBMCs of five
other donors, in all cases the result was the same (Fig 5 and S4 Fig). Differences in the IL-10
release after incubation with LPS indicated differences in responding of different PBMCs
(Panel A in S4 Fig). In addition, an experiment was performed adding increasing amounts of
plasmid (Panel C and D in S4 Fig). Increasing amounts of plasmid were not associated with an
increase in the IL-10 release, this indicates, that the plasmids used for transfection were not
contaminated with residual LPS after the purification and washing procedure.
Discussion
Here for the first time two new expression vector systems were designed and used to express
the ISU domain of three different retroviruses and to present them to human PBMCs in order
to study their ability to induce IL-10 as marker of immunosuppression. The first expression
system is based on the expression and release of parts of the TM proteins containing the ISU
domain (pOUT) (Fig 1), the second on the expression of the ISU domain using a CD82 anchor
(tANCHOR) (Fig 4). In this study two gammaretroviruses (PERV, MuLV) and one lentivirus,
HIV-1, were analysed. The sequences of the ISU domains of gammaretroviruses, betaretro-
viruses and lentiviruses are related, but not identical [14]. The sequences of the ISU domains
of the gammaretroviruses MuLV, PERV, KoRV and FeLV are 100% identical [14], however
there are sequence differences in the N and C terminal regions (Fig 2). Although a significant
IL-10 release as a marker of an immunosuppressive activity was observed when human
PBMCs were co-incubated with cells expressing and releasing (pOUT) or presenting the CD82
anchored ISU domain (tANCHOR), the same level of IL-10 release was observed with cells
expressing the mutated ISU domains (Fig 5 and S4 Fig). This means that either the mutation
did not inactivate the IL-10-inducing activity of the ISU domain or another heat-labile protein
is biological active.
The need for an “one-pot protein expression and IL-10 validation system” secreting pro-
teins into the supernatant or presenting proteins on the surface of human cells emerged
Retroviral immunosuppressive domains
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because LPS is also able to induce IL-10 and possible contaminations in other assay systems
could not be excluded. It was shown in the past that primary human immune cells are highly
sensitive to LPS and can be activated by LPS concentrations as low as 0.02 ng/ml [43]. Particu-
larly, the fact that protein concentration procedures may be associated with increased LPS con-
centrations [44] made it necessary to avoid experimental designs were proteins have to be
concentrated. All reagents in the laboratory are associated with the potential risk of an endo-
toxin contamination. During previous experiments using recombinant gp41 produced in
human cells and including methods to remove endotoxin, differences in the induction of cyto-
kines by gp41 and LPS have been observed. For example proteins encoded by the genes serpine
E1, IL1Ra, uPAR, PDGF-AA, thrombospondin-1, myeoloperoxidase and osteopontin have
Fig 5. Analysis of IL-10 release after incubation of cells expressing the pOUT and tANCHOR constructs. (A) HeLa cells transfected with an indicated amount of
DNA encoding the pOUT constructs WT and MUT HIV, WT and MUT PERV were incubated with human PBMCs from four different donors (the number indicate
day/month of the experiment) and the IL-10 release was measured using an IL-10 ELISA. Different concentrations of LPS added to the cells were used as positive
control, non-transfected HeLa cells were used as negative control. The error bars mean SD. The calculated p-values for the difference between the IL-10 release pf
PBMCs incubated with untreated HeLa cells or with HeLa cells expressing pOUT with wt oder mut sequences was 5.93E-11. (B) The same for the pOUT constructs WT
and MUT MuLV and PBMCs from three different donors. (C) IL-10 release induced by concentrated supernatants (40x) collected from HEK293T cells transfected with
the pOUT constructs. Each well was incubated with 50 μl 40x concentrated supernatant before and after heat treatment. The p-values for the difference between the
heat-inactivated supernatant and the untreated material were 0.0082 for HIV wt and mut, 0.067 for MuLV wt and mut, and 0.026 for PERV wt and mut. Concentrated
supernatant from non-transfected 293 cells (native and heat inactivated) as well as PBMCs alone were used as control.
https://doi.org/10.1371/journal.pone.0200570.g005
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been induced by gp41 containing the ISU domain, but not by the LPS used [31]. However,
under certain conditions these proteins have also been induced by defined LPS batches [45–
51]. Furthermore, lipopolysaccharides from distinct pathogens induce different classes of
immune responses in vivo [52]. However, when the concentrated samples were heat-inacti-
vated, a significant loss of activity was observed despite the fact, that residual IL-10 induction
is possibly due to a heat-resistant endotoxin (Fig 5C). LPS is stable at the temperature of 98˚C
used [53]. Although the loss indicates a protein as source, no differences between the activities
of the wild-type or mutated ISU domain were observed. As mentioned above, either the muta-
tions used did not inactivate the IL-10 inducing activity of the ISU domain or another protein
was involved.
The data presented here are consistent with our previous results showing an absence of IL-
10 release after incubation of human PBMCs with human melanoma cells expressing the TM
protein of HERV-K, with human cells producing PERV and with human cells expressing the
TM protein gp41 of HIV-1 [54]. The data are also in line with observations by Hummel et al.
[55], showing that the Env proteins containing the ISU domain from three HERVs (syncytin-
1, which is the Env of HERV-W; syncytin-2, which is the Env of HERV-FRD and the Env of
HERV-K) expressed as recombinant proteins on the surface of Chinese hamster ovarial
(CHO) cells did not induce IL-10. In contrast, the human choriocarcinoma cells naturally
expressing these three proteins, syncytin-1, syncytin-2, and the Env protein of HERV-K on
their surface, induced IL-10 expression by dendritic cells [55]. These data suggest that the
amount of proteins expressed after transfection, or their conformation is not sufficient to
interact with a putative receptor and to induce IL-10 [54, 55]. Especially in the our case of the
ISU domain expressed in CD82 with its four membrane-spanning domains it may be expected
that larger neighbouring proteins are the reason of steric hindrance. We cannot exclude that
additional factors expressed in human choriocarcinoma cells may interfere with the Env pro-
teins and trigger the immunosuppressive activity.
The absence of IL-10 induction after incubation of cells expressing and releasing the ISU
domain reported here and previously [54, 55] is in contrast to numerous results obtained with
synthetic peptides corresponding to the ISU domain or TM proteins of different retroviruses
including HIV-1 (for review see [14]). Synthetic peptides corresponding to the ISU domain of
HIV-1 conjugated to BSA [17, 18, 20] or in the form of homopolymers [26], had been shown
to inhibited proliferation of human PBMCs. The conformation of the ISU domains induced
by conjugation to a carrier protein or homopolymerisation seems to be important for the bio-
logical activity since ISU peptide monomers did not show immunosuppressive properties.
Recombinant or purified viral TM proteins from different retroviruses such as HIV-1 [27–31],
HERV-K [56], and FeLV [57–60] also inhibited proliferation of PBMCs and modulated cyto-
kine release including an increase in the release of IL-10, whereas for example the Gag protein
of FeLV was inactive. Non-infectious virus particles of PERV [56], FeLV [60–62], KoRV [63],
HERV-K [56] and HIV-1 [30] were also able to inhibit mitogen-triggered lymphocyte prolifer-
ation, and to modulate cytokine release and gene expression. On the other hand it cannot be
excluded that in some experimental settings using purified virus preparations or concentrated
recombinant proteins these might have been contaminated by microbial components such as
LPS. However, this seems highly unlikely in the cases mutants of the ISU domain have been
compared with the wild-type ISU domain in vitro [14, 30] and in vivo, in mice [16, 32, 33].
The mechanism how the ISU domain interacts with immune cells is still unclear. There are
several reports showing binding of the TM proteins or synthetic peptides corresponding to the
ISU domain to monocytes and B cells [64–68].
It is well known that infection of natural hosts, e.g., sooty mangabeys with simian immuno-
deficiency viruses (SIV) is non-pathogenic despite high viremia [69]. SIV contain a functional
Retroviral immunosuppressive domains
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ISU domain and may induce immunodeficiencies in non-natural hosts, e.g., rhesus monkeys.
As proposed earlier, if the ISU domain plays a substantial role in the induction of the immuno-
deficiency, their receptor or the corresponding signal transduction should be non-functional
in the natural host [14]. Interestingly, recently a 17-amino acid longer sequence of the toll-like
receptor 4 (TLR-4) associated with a reduced response to TLR-4 ligands including LPS was
found in all natural hosts of SIV, but not in non-natural host [70]. It is important to learn how
the longer TLR-4 and other genetic changes in natural hosts prevent the outbreak of the
immunodeficiency.
To summarise, the immunosuppressive domain is highly conserved among different retro-
viral genera. Synthetic peptides corresponding to this domain, recombinant and viral trans-
membrane envelope proteins and non-infectious particles of several retroviruses including
HIV-1 have been shown to have an immunosuppressive activity, modulating the cytokine
release of normal human PBMCs and modulating the gene expression in these cells [14, 26]
(Table 1). Tumour cells not growing to tumours in immunocompetent mice grow to tumours
when expressing the transmembrane protein of different retroviruses, indicating the immuno-
suppressive activity of these proteins [15, 16, 32]. Single mutations in the ISU domain abro-
gated their immunosuppressive activity [16, 30, 32]. In contrast, the expressed TM proteins of
PERV, MuLV and HIV-1 described here as well as cells expressing the ISU domains of three
HERV (W, FRD, K) [54, 55] were unable to induce IL-10 for reasons still to be elucidated. One
conclusion from these investigations is the consideration, not to use only IL-10 measurement
as a marker for an immunosuppressive property since LPS may always interfere. Therefore
other assays and analysis platforms should be established to measure immunosuppressive
activities of retroviral proteins. In addition, efforts should be undertaken to present the ISU
domains in a conformation and/or multiplicity, e.g., containing multiple ligands to interact
with a complex receptor, as found in the retrovirus infected individual [14].
Materials and methods
Cloning of expression constructs
Two expression systems were developed, one expressing and secreting the TM protein con-
taining the ISU domain, designated pOUT expression constructs, the other expressing part of
the TM protein including the ISU domain on the cell surface, using the CD82 tetraspanin, des-
ignated the tANCHOR system.
Table 1. Differences in the immunosuppressive properties of retroviral TM proteins.
Retroviral TM proteins showing immunosuppression Retroviral TM proteins NOT showing
immunosuppression
Three HERV Env proteinsa) naturally expressed on
human choriocarcinoma cells [55]
Three HERV Env proteinsa) expressed as recombinant
proteins on CHO cells [55]
Retroviral TM proteinsb) expressed in a tumour cell
rejection model [15, 16, 32]
HERV-K Env protein naturally expressed on
teratocarcinoma cells [54]
Numerous purified viruses, viral TM proteins and
peptides corresponding to the isu domain [13, 14, 17–
33, 56–60]
ISU domains of HIV-1, PERV, and MulV, presented by
the pOUT or tANCHOR systems on human cells (this
study)
a)Syncytin-1, which is the envelope protein of HERV-W, syncytin-2, that of HERV-FRD, and the Env protein of
HERV-K (HML-2)
b)Murine gammaretrovirus, type D retrovirus, HERV-H, ERV3, HERV-p(B9), HERV-V, syncytin-1 (HERV-W),
syncytin-2 (HERV-FRD), syncytin-A, syncytin-B
https://doi.org/10.1371/journal.pone.0200570.t001
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The pOUT expression constructs were generated by using the gene synthesis fragments
SEQ ID 01 and 02 which represents the wild-type (wt) and mutated (mut) ectodomain of the
transmembrane envelope protein gp41 of HIV-1 (aa 535–573, Genbank accession no.
JQ975395.1, S1 Fig), SEQ ID 3 and 4 the wt and mut ectodomain of p15E of PERV (aa 477–
585, Genbank accession no. AY312520.1), and SEQ ID 5 and 6 the wt and mut ectodomain of
p15E of the Friend-MuLV (aa 458–566, Genbank accession no. GQ420673.1). The sequences
including the ISU domain or the mutants in the ISU domain (Fig 2A) were cloned using the
flanking NdeI/NcoI restriction sites in the vector pA4E211-FlexTEC (ATG:biosynthetics, Frei-
burg, Germany). These constructs contain a signal peptide derived from Gaussia princeps (Fig
2A), for improving the secretion efficiency [34]. The pA4E211-FlexTEC vector (ATG:biosyn-
thetics, Merzhausen, Germany) contained a puromycin resistance marker.
The tANCHOR system was used to express retroviral TM proteins on the surface and con-
structed using the pCMVtag2B vector (Stratagene, Heidelberg, Germany) as backbone. The
tetraspanin CD82 sequence (codons 1–267, accession no. NM_002231.3) was introduced
instead of the CD63 sequence into the vector pCMV-CD63-YFP-FLAG [63] using the res-
triction sites NotI/XhoI and the synthetic gene fragment SEQ ID 07 (S1 Fig). In the same
way the CD82-anchored sequence lacking the large extracellular loop (ΔLEL) was generated
using the synthetic gene fragment SEQ ID 08, the restriction sites NotI/XhoI and the vector
pCMV-CD63-mCherry-FLAG. This vector backbone was used to introduce retroviral ISU
domain sequence elements SEQ IDs 9–12 (S1 Fig). The pCMVtag2B vector contains a neomy-
cin selection marker. All constructs were verified by Sanger sequencing and restriction
analysis.
The cloning sequence for the expression of the HHV6 protein was codon-optimised by the
JAVA codon adaptation tool (JCAT) algorithm for E. coli expression (SEQ ID 13) and synthe-
sised by ATGbiosynthetics (Merzhausen, Germany). The synthetic gene sequences were
cloned into the expression vector pet16b (Novagen, Madison, WI, USA) using the restriction
enzymes NdeI and XhoI (New England Biolabs). The cloned sequences were confirmed by
Sanger sequencing.
BL21 E. coli competent cells (New England Biolabs) were transformed with the vector
pet16B. The expression and isolation was performed similar as previously described [71]. The
protocol was slightly changed and the overnight culture was diluted to an optical density at
600 nm wavelength (OD600) of 0.1 in 2 L 2YT-Medium. E. coli culture was shaken for 5 hrs
without IPTG induction. All other steps were performed as previously described [72]. The
fractions were separated by TGX Gels (BioRad, Munich, Germany) and stained with Coomas-
sie blue solution (0.1% Coomassie Blue R250, 10% acetic acid, 40% methanol).
Cell cultivation and transfection
HeLa (ATCC CCL2) or HEK293T (CRL-3216) cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS, Biochrom AG, Ber-
lin, Germany), 100 IU/mL penicillin, 100 μg/mL streptomycin (PAA Laboratories, Cölbe, Ger-
many), and 2 mM L-glutamine (Biochrom AG). FCS had been tested and was shown not to
induce IL-10 in an assay described below. Cells were trypsinised and seeded in 6, 96 well plates
(TPP, Munich, Germany) or for cLSM analysis in ibiTreat 8-well slides (IBIDI, Munich, Ger-
many). After 24 h cells were transfected with the corresponding vector construct expressing
the ISU domain and pCMV-CD82-YFP as control adding 2 μl of MetafectenePro (Biontex,
Munich, Germany per well of a 96 well plate/ ibiTreat 8-well slides containing 2 x104 Hela cells
one day before transfection or 20 μl of MetafectenePro per well of a 6 well plate containing 0.5
x106 HEK293T or HeLa cells. Transfection procedures were done at a confluency of approx.
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80%. To prevent mycoplasma contamination cells were cultivated with DMEM medium sup-
plemented with 10% FCS (Biochrom AG, Berlin, Germany) and an antibiotic mix containing
tylosine 40 μg/ml (Sigma Aldrich, Steinheim, Germany), ciprofloxacin 20 μg/ml (Sigma
Aldrich, Steinheim, Germany), and gentamycin 20 μg/ml (Applichem, Darmstadt, Germany)
as well as 2 mM L-glutamine (Biochrom AG) until co-cultivation with PBMCs. All cells were
maintained in an incubator at 37˚C, 95% relative humidity and 5% CO2. All cells were myco-
plasma free after tests described below.
Analysis of protein expression by confocal laser scanning microscopy
(cLSM)
Cells were fixed 24 hrs after transfection with 2% paraformaldehyde dissolved in PBS for 20
min, then washed with PBS and leaved in 200 μl 1xPBS + 20 μl Duolink mounting medium
(Sigma Aldrich, Germany). Fixed cells were Images were obtained using a Zeiss LSM 780 confocal
laser scanning inverted microscope (Carl Zeiss, Oberkochen, Germany) using a 63× oil immer-
sion objective. The fluorescently-tagged proteins were detected employing a ZEISS ZEN smart set
up instrument using the settings for 4,6-diamidino-2-phenylindole (DAPI), YFP and mCherry.
Analysis of secreted proteins by Western blotting, ELISA and enhanced
chemiluminescence
Secreted poly-histidine tagged proteins were isolated from pooled cell culture supernatants
after centrifugation for 10 min at 2000 rpm in order to remove cell debris. The supernatants
were incubated with 50 μl Dynabeads His-Tag (Invitrogen), incubated for 20 min at room
temperature and washed the Dynabeads following manufactures instructions. After elution of
poly-histidine tagged proteins with 50 μl His-elution buffer (300 mM imidazole, 50 mM
sodium phosphate pH 8.0, 300 mM NaCl, 0.01% Tween-20), 50 μl of Laemmli buffer 2X were
added and a SDS-PAGE using TGX gels (BioRad, Munich, Germany) was performed. The
proteins were transferred onto Immobilon-P PVDF membranes (Millipore, Schwalbach, Ger-
many). Blots were probed with 0.6 μg/mL of mouse anti-V5 antibodies labelled with horserad-
ish peroxidase (HRP) (Invitrogene) or 0.5 μg/mL mouse anti-mCherry antibodies (Abcam,
Cambridge, UK) and visualised with Pierce ECL Western blotting substrate (Thermo Scien-
tific, Bonn, Germany). Western blot images were acquired using a Chemocam device (Intas,
Göttingen, Germany) with implemented contrast correction.
Quantification of the secreted proteins was performed using the HHV6-derived protein
(fraction B6, Panel A in S2 Fig) as standard for an ELISA. Ni(2+) chelate-coated 96 well plates
(Pierce™ Nickel Coated Plates, Clear, Thermo Scientific, Dreieich, Germany) were pre-blocked
with BSA and incubated with 50 μl of 40 x concentrated by ultrafiltration (Vivaspin20 columns,
Sartorius, Göttingen, Germany) cell culture supernatant and 50 μl of the HHV6 protein (1:100
diluted in PBS) for 1 hr. Wells were washed three times with 200 μl of PBS/0.05% Tween-20,
100 μl of goat anti-6xHis-HRP antibody (Cat. No. 1269, Cambridge, United Kingdom) diluted
1:5000 in 5% BSA/PBS per well was added and incubated for 1 hour at room temperature. After
washing five times with 200 μl of PBS/0.05% Tween20 the absorbance was determined.
Isolation of human PBMCs
PBMCs were isolated from whole blood of healthy donors by Ficoll-Hypaque (PAA Laborato-
ries, Austria) density centrifugation using Leucosep tubes (Greiner, Germany). PBMCs were
cultivated at 37˚C in RPMI 1640 with 10% FCS (Biochrome AG, Berlin, Germany) which had
been selected for very low induction of IL-10 in normal human PBMCs.
Retroviral immunosuppressive domains
PLOS ONE | https://doi.org/10.1371/journal.pone.0200570 July 12, 2018 12 / 18
IL-10 assay
2 x104 Hela cells were seeded per well of an 96 well plate and grown until the cells reached a
confluency of approximately 80%. Cells were transfected with one of the plasmid DNA and 2 μl
per well with MetafectenePro (Biontex, Munich, Germany). Cells were washed 3 times and co-
cultivated with 3x105 PBMCs per well overnight. In case of testing concentrated supernatant we
incubated 105 ng of His tagged retroviral protein (dilutions in 200 μl media) with 3x105 PBMCs
per well. On the next day 100 μl of the supernatants were collected, centrifuged at 2000 g for 10
min and IL-10 secretion was tested by ELISA (BD Biosciences, San Diego, USA) technique.
ELISA
96 wells plates (Nunc MaxiSorp, Thermo scientific, Germany) were coated with 100 μl of 1 μM
synthetic peptide Biot-Ahx-Ahx-KQLQARILAVERYLKDQQL (Genaxxon, Germany) in car-
bonate buffer (15 mM Na2CO3, 35 mM NaHCO3, 0.2 g/L NaN3, pH 9.6) by overnight incuba-
tion at 4˚C. The plates were washed three times with 300 μl/well wash buffer (1xPBS
containing 0.05% Tween 20) and blocked for 2 hrs with 200 μl blocking buffer (3% bovine
serum albumin in 1xPBS). Blocking buffer was replaced by 100 μl a dilution of purified IgG of
the monoclonal antibody B3 obtained by immunisation of a mouse with an conjugate of the
ISU peptide to bovine serum albumin (BSA). Primary IgG incubated for 1 hr and wells were
washed 5 times with wash buffer. The primary antibody was detected by 100 μl/per well of
0.43 μg/ml anti-mouse HRP (DAKO, Denmark). After 1 hr plates were washed with 300 μl/per
well washing buffer 5 times. Parallel in a 96 well plate (tissue culture test plate 96F, TPP, Swit-
zerland) 2 x 104 HeLa cells were seeded and transfected at confluency of 80% with the tAN-
CHOR construct pCMV-CD82ΔLEL-HIV WT-mCherry (0.6 μg plasmid DNA per well, 2 μl
MetafectenePro) for expressing the wt ISU domain of HIV-1. Non-transfected HeLa cells
served as control. After 24 hrs Hela cells were fixed with 2% paraformaldehyde in 1xPBS for 30
min and washed two times with 300 μl of 1xPBS. Hela cells were blocked for 2 hrs with 200 μl
blocking buffer (3% bovine serum albumin in 1xPBS), all further steps were performed as
described for the peptide ELISA. The secondary antibody was detected by adding 100 μl of
TMB (3,3’,5,5’-tetramethylbenzidine) substrate (TMB substrate kit, Thermo Fisher) into each
well and incubated at room temperature in dark for 15–30 min. After blue color development
100 μL of stop solution (0.16M H2SO4) was added. The absorbance of all wells was measured
at 450 nm using a microplate reader (MultiscanTMGO, Thermo Scientific).
LAL-test
The level of endotoxin was measured using the LAL-test kit from Thermofisher (Thermo Sci-
entific, Braunschweig, Germany).
Mycoplasma testing
Hela and HEK293T cells were tested for mycoplasma contamination (GATC Biotech, Kon-
stanz, Germany) using the service MYCOPLASMACHECK.
Ethical statement
The use of human blood has been approved by the ethical commission at the Medical Faculty
of the Humboldt University Berlin. Written informed consent was provided by study
participants.
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Supporting information
S1 Fig. Nucleotide sequences of the TM domains containing the ISU domain of all pOUT
and tANCHOR constructs used. The accession numbers of the sequences are displayed in the
section material and methods.
(DOCX)
S2 Fig. Characterisation of the HIS tagged gB protein of HHV-6. (A) Coomassie blue
stained gel electrophoresis of the HHV-6 protein which was expressed and purified using His
tag affinity chromatography, Fraction B6 was identified as pure protein, (B) fraction B6 was
used for a colour response standard curve in order to calculate the amount of His tagged pro-
teins.
(TIF)
S3 Fig. Evidence that the expression of the WT and MUT HIV-1 and the WT and MUT
PERV constructs was identical. Fluorescence (left column) and bright field (right column)
microscopy image of HeLa cells expressing the CD82 anchored retroviral protein sequences
tagged C-terminally with mCherry.
(TIF)
S4 Fig. (A) Differences in the release of IL-10 from PCMCs of six different donors. The
PBMCs of six different donors were incubated with the same amount of LPS (10 ng/ml) and
the IL-10 release value was measured in an ELISA. (B) Dose dependence of IL-10 induction
by LPS. (C, D) Analysis of IL-10 release adding different amounts of plasmid. Different
amounts of plasmids encoding (C) tANCHOR and (D) pOUT were added. All measurements
were performed in triplicates. The calculated p-values for the difference between the IL-10
release pf PBMCs incubated with untreated HeLa cells or with HeLa cells expressing the tAN-
CHOR constructs with wt oder mut sequences 5.81E-12.
(TIF)
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